{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:09:06Z","timestamp":1772521746132,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to assess the effects of cognitive behavioral therapy (CBT) combined with aripiprazole on clinical symptoms, cognitive function, and emotional state in patients with schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center retrospective controlled design was used, with data from the electronic medical records of the psychiatry department of Liupanshui Shuikuang hospital. A total of 168 patients were included and divided into two groups based on whether they received structured CBT intervention: the combined treatment group (aripiprazole + CBT) and the monotherapy group (aripiprazole only), with 84 patients in each group. Propensity score matching was used to reduce bias, and the clinical symptoms, cognitive function, and emotional state of patients were evaluated at baseline (T0), 3 months (T1), and 6 months (T2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The combined treatment group showed significant improvements in Positive and Negative Syndrome Scale (PANSS) total score, Montreal Cognitive Assessment (MoCA) score, Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder 7 (GAD-7) compared to the monotherapy group (P &amp;lt; 0.05). In terms of quality of life, the combined treatment group showed significantly greater improvement in Schizophrenia Quality of Life Scale (SQLS) total score compared to the monotherapy group (P = 0.006). Multivariate regression analysis revealed that CBT combined treatment significantly enhanced the improvement in PANSS total score and MoCA score, and was associated with reductions in depression and anxiety symptoms. An increase in treatment frequency and intensity further enhanced efficacy. Subgroup analysis showed better treatment responses in younger patients and those with a shorter disease duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CBT combined with aripiprazole significantly improves the psychiatric symptoms, cognitive function, and emotional state of patients with schizophrenia, and the frequency and intensity of treatment have a positive impact on efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1777230","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:47:44Z","timestamp":1772520464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive behavioral therapy combined with aripiprazole in the treatment of schizophrenia: effects on cognitive function and psychological state"],"prefix":"10.3389","volume":"17","author":[{"given":"Neng","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huicong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.717715","article-title":"Dose-dependent efficacy of aripiprazole in treating patients with schizophrenia or schizoaffective disorder: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Qian","year":"2021","journal-title":"Front Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00406-022-01526-1","article-title":"Effects of psychological treatments on functioning in people with Schizophrenia: a systematic review and meta-analysis of randomized controlled trials","volume":"273","author":"Bighelli","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2011.577188","article-title":"Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials","volume":"65","author":"Sarin","year":"2011","journal-title":"Nordic. J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e34827","DOI":"10.1097\/MD.0000000000034827","article-title":"The application of cognitive behavioral therapy in patients with schizophrenia: A review","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009608.pub2","article-title":"Cognitive behavioural therapy (group) for schizophrenia","author":"Guaiana","year":"2022","journal-title":"Cochrane Database System. Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102392","article-title":"Cognitive behavioural therapy for the treatment of schizophrenia spectrum disorders: an umbrella review of meta-analyses of randomised controlled trials","volume":"67","author":"Berendsen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm114","article-title":"Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor","volume":"34","author":"Wykes","year":"2008","journal-title":"Schizophr Bull"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.31083\/AP38775","article-title":"Effect of paliperidone combined with sertraline in the treatment of schizophrenia and its influence on serum neurofunctional related factors","volume":"26","author":"Gu","year":"2025","journal-title":"Alpha. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13020215","article-title":"Impact of cognitive impairments on health-related quality of life in schizophrenia","volume":"13","author":"Rekhi","year":"2023","journal-title":"Brain Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12888-019-2248-7","article-title":"Subjective quality of life among patients with schizophrenia spectrum disorder and patients with major depressive disorder","volume":"19","author":"Tan","year":"2019","journal-title":"BMC Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1583630","article-title":"Influence of illness perception on depression and anxiety in individuals with schizophrenia during the COVID-19 pandemic","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1366030","article-title":"The relationship between self-stigma and quality of life in long-term hospitalized patients with schizophrenia: a cross-sectional study","volume":"15","author":"Liu","year":"2024","journal-title":"Front Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1017\/neu.2025.14","article-title":"Application of cognitive behavioural therapy combined with aripiprazole in the treatment of schizophrenia: a randomised controlled trial","volume":"37","author":"Yan","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e39572","DOI":"10.1097\/MD.0000000000039572","article-title":"Cognitive-behavioral therapy for negative symptoms of schizophrenia: A systematic review and meta-analysis","volume":"103","author":"Xu","year":"2024","journal-title":"Medicine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0324685","DOI":"10.1371\/journal.pone.0324685","article-title":"Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Hong","year":"2025","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291723003070","article-title":"Which psychological interventions improve quality of life in patients with schizophrenia-spectrum disorders? A meta-analysis of randomized controlled trials","volume":"54","author":"Petkari","year":"2024","journal-title":"psychol Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbs105","article-title":"Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial","volume":"38","author":"van der Gaag","year":"2012","journal-title":"Schizophr Bull"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.112.116285","article-title":"Cognitive\u2013behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias","volume":"204","author":"Jauhar","year":"2014","journal-title":"Br J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40359-018-0243-2","article-title":"Cognitive Behavioural Therapy for schizophrenia-outcomes for functioning, distress and quality of life: a meta-analysis","volume":"6","author":"Laws","year":"2018","journal-title":"BMC Psychol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300213","article-title":"Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review","volume":"65","author":"Burns","year":"2014","journal-title":"Psychiatr Serv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1653144","article-title":"Glymphatic system dysfunction in young adults hospitalized for an acute psychotic episode: A preliminary report from a pilot study","volume":"16","author":"Barlattani","year":"2025","journal-title":"Front Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1642605","article-title":"Glymphatic system and psychiatric disorders: Need for a new paradigm","volume":"16","author":"Barlattani","year":"2025","journal-title":"Front Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2005.02.018","article-title":"The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis","volume":"77","author":"Zimmermann","year":"2005","journal-title":"Schizophr Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1017\/S1352465813000428","article-title":"Cognitive behavioral therapy and work outcomes: correlates of treatment engagement and full and partial success in schizophrenia","volume":"42","author":"Kukla","year":"2014","journal-title":"Behav Cogn Psychother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291724003088","article-title":"Brain structural damage networks at different stages of schizophrenia","volume":"54","author":"Xu","year":"2024","journal-title":"psychol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01426-x","article-title":"Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes","volume":"48","author":"Howes","year":"2023","journal-title":"Neuropsychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1777230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:47:45Z","timestamp":1772520465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1777230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":26,"alternative-id":["10.3389\/fpsyt.2026.1777230"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1777230","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1777230"}}